“Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall”, sjo, vol. 8, no. 2, pp. 478–485, Jun. 2026, doi: 10.37275/sjo.v8i2.137.